626 Financial’s Precision BioSciences DTIL Stock Holding History

626 Financial’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-439	Closed	-$4.81K	–	109
2023 Q4	$4.81K	Hold	439	–	–	﹤0.01%	105
2023 Q3	$4.5K	Hold	439	–	–	﹤0.01%	107
2023 Q2	$6.93K	Buy	+439	New	+$10K	﹤0.01%	114

Other funds holding DTIL

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MSAM

Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return

626 Financial's DTIL Position: Q1 2024 in Review

626 Financial sold out of Precision BioSciences (DTIL) in Q1 2024, closing a stake of 439 shares — an estimated $4.81K sold.

626 Financial first reported a position in DTIL in Q2 2023 and held it in 3 quarters. The position peaked at $6.93K in Q2 2023. 43 funds tracked by Wall St. Rank hold DTIL as of Q1 2024.

626 Financial reported no remaining Precision BioSciences position as of Q1 2024 after selling out during the quarter.
626 Financial sold 439 Precision BioSciences shares in Q1 2024, an estimated $4.81K.
626 Financial first reported a position in Precision BioSciences in Q2 2023 and held it in 3 quarters.
626 Financial's Precision BioSciences position peaked at $6.93K in Q2 2023.
43 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2024.

Based on 626 Financial's 13F filing for Q1 2024, filed 18 Apr 2024.